Crossmark Global Holdings Inc. Raises Stake in Cencora, Inc. $COR

Crossmark Global Holdings Inc. raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 59.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,477 shares of the company’s stock after acquiring an additional 6,906 shares during the period. Crossmark Global Holdings Inc.’s holdings in Cencora were worth $6,241,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Oakworth Capital Inc. bought a new stake in shares of Cencora in the 4th quarter worth approximately $26,000. Archer Investment Corp grew its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the last quarter. IAG Wealth Partners LLC purchased a new position in Cencora in the 3rd quarter worth $30,000. Cloud Capital Management LLC bought a new stake in Cencora in the third quarter worth $31,000. Finally, Caitlin John LLC bought a new stake in Cencora in the third quarter worth $31,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora raised FY2026 EPS guidance to $17.65-$17.90 and resumed a $1 billion share repurchase program, signaling management confidence in earnings power and capital returns.
• Positive Sentiment: Several Wall Street firms still maintained bullish ratings after cutting price targets, including Citi and Baird, suggesting analysts continue to see upside despite the selloff.
• Neutral Sentiment: Commentary around the stock emphasizes a “valuation debate” and whether the post-earnings decline was overdone, indicating investors are reassessing expectations rather than reacting to a new operational shock. Cencora NYSE Composite Reset Sparks Valuation Debate
• Neutral Sentiment: Analyst and media coverage is also centered on margin expansion versus growth, reflecting debate over whether Cencora is prioritizing profitability and buybacks over top-line momentum. Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks?
• Negative Sentiment: The main bearish driver is the earnings report, which missed EPS estimates and came with sales below analyst expectations, raising concerns about near-term growth momentum. Cencora (NYSE:COR) reports sales below analyst estimates in Q1 CY2026 earnings
• Negative Sentiment: A securities fraud investigation announcement could add overhang and legal-risk concerns, potentially worsening sentiment until more details are known. Securities Fraud Investigation Into Cencora, Inc. (COR) Announced

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Morgan Stanley set a $342.00 price objective on Cencora in a research note on Friday. William Blair started coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. JPMorgan Chase & Co. raised their price target on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Evercore set a $360.00 price objective on Cencora in a research report on Wednesday, April 8th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $388.42.

Cencora Price Performance

COR stock opened at $261.16 on Monday. The stock has a market capitalization of $50.80 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 1.21 and a beta of 0.64. The firm’s 50-day moving average price is $327.81 and its two-hundred day moving average price is $342.26. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the prior year, the company posted $4.42 earnings per share. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts predict that Cencora, Inc. will post 17.73 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.